Cancer NetworkOriginal article
<![CDATA[Ponatinib/Blinatumomab Regimen Improves EFS in Ph-Positive ALL]]>
Data ReadoutpositivePonatinibBlinatumomabPositive
AI Analysis
Summary
A ponatinib plus blinatumomab regimen improved event-free survival in Ph-positive acute lymphoblastic leukemia, potentially allowing a meaningful subset of patients to forego transplant.
Clinical Trial Data
Outcome Details
Ponatinib plus blinatumomab regimen improved event-free survival (EFS) in Ph-positive ALL and may allow a meaningful subset of patients to forego transplant.
Importance:5/10
Sentiment:
0.60
ponatinibblinatumomabPh-positive ALLacute lymphoblastic leukemiaevent-free survivaltransplant-freeoncologyhematologic malignancy
Read the original article
Published by Cancer Network on October 17, 2026 6:00 PM